肝细胞癌中18F-FDG与68Ga-PSMA-11摄取异质性一例
一例87岁男性黑色素瘤肺转移患者发现FDG阴性肝病灶,随访CT示病灶增大,活检确诊原发性肝细胞癌。FDG PET/CT示摄取仅略高于肝本底,而68Ga-PSMA-11 PET/MR示肿瘤不同区域局灶性浓聚,提示瘤内代谢异质性。
要点
- 肝细胞癌可表现为FDG阴性或仅略高于肝本底摄取。
- 同一肝细胞癌内FDG与PSMA摄取可位于不同区域。
- FDG阴性肝病灶在随访增大时应考虑活检明确诊断。
核心结论
- 肝细胞癌可表现为FDG阴性而68Ga-PSMA-11在肿瘤不同区域局灶性浓聚,支持瘤内代谢异质性。
研究设计与样本
- 单例病例报告:87岁男性,黑色素瘤肺转移史,发现FDG阴性肝病灶。
主要发现
- FDG PET/CT示肝病灶FDG摄取极低,仅略高于肝本底。
- 68Ga-PSMA-11 PET/MR示肿瘤不同区域局灶性浓聚放射性示踪剂。
- 活检证实肝病灶为原发性肝细胞癌。
临床怎么用
- 对FDG阴性肝病灶,尤其随访增大者,不应默认良性,应结合活检。
- 怀疑肝细胞癌且FDG阴性时,可考虑68Ga-PSMA-11显像评估瘤内异质性。
局限性
- 单例病例报告,结论不能推广至所有肝细胞癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present the case of an 87-year-old man with a history of melanoma metastatic to the lungs found to have an FDG-negative liver lesion that was initially thought to be benign. Follow-up CT revealed growth of the liver lesion despite excellent response to nivolumab therapy of the pulmonary melanoma metastases. Biopsy of the lesion confirmed primary hepatocellular carcinoma. Follow-up F-FDG PET/CT showed minimal FDG uptake, slightly above liver background, and subsequent Ga-PSMA-11 PET/MR showed focal, intense uptake of radiotracer in a different region of the tumor. These imaging findings support intratumor metabolic heterogeneity with radiotracer uptake in different tumor locations.
引用
- Perez PM, Flavell RR, Kelley RK, et al. Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma. Clin Nucl Med. 2019. PMID: 30624275. doi:10.1097/RLU.0000000000002452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。